Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Subsidiary Hangzhou Mipeng to Invest 15 Million Yuan in Partnership Enterprise, Focusing on Biomedicine and Hard Technology Strategic Emerging Industries

Stock News09-22

Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that its controlled entity, Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) ("Hangzhou Mipeng"), plans to participate in subscribing to shares of Xihu Innovation (Hangzhou) Technology Innovation Achievement Transformation Venture Capital Partnership (Limited Partnership). Hangzhou Mipeng signed the Partnership Agreement on September 19, 2025. As a limited partner, Hangzhou Mipeng intends to subscribe to the corresponding capital contribution with 15 million yuan of its own funds. The partnership enterprise's investment objectives are to primarily conduct venture capital activities targeting companies in strategic emerging industries such as biomedicine and hard technology, focusing on investment opportunities in early-stage, small and medium-sized, and growth-stage enterprises.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127117941?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-22 18:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127117941","market":"us","top_or_hot":-1,"title":"Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Subsidiary Hangzhou Mipeng to Invest 15 Million Yuan in Partnership Enterprise, Focusing on Biomedicine and Hard Technology Strategic Emerging Industries","media":"Stock News","content":"<p>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that its controlled entity, Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) (\"Hangzhou Mipeng\"), plans to participate in subscribing to shares of Xihu Innovation (Hangzhou) Technology Innovation Achievement Transformation Venture Capital Partnership (Limited Partnership). Hangzhou Mipeng signed the Partnership Agreement on September 19, 2025. As a limited partner, Hangzhou Mipeng intends to subscribe to the corresponding capital contribution with 15 million yuan of its own funds. The partnership enterprise's investment objectives are to primarily conduct venture capital activities targeting companies in strategic emerging industries such as biomedicine and hard technology, focusing on investment opportunities in early-stage, small and medium-sized, and growth-stage enterprises.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Subsidiary Hangzhou Mipeng to Invest 15 Million Yuan in Partnership Enterprise, Focusing on Biomedicine and Hard Technology Strategic Emerging Industries</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHangzhou Bio-Sincerity Pharma-Tech (301096.SZ) Subsidiary Hangzhou Mipeng to Invest 15 Million Yuan in Partnership Enterprise, Focusing on Biomedicine and Hard Technology Strategic Emerging Industries\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-22 18:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that its controlled entity, Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) (\"Hangzhou Mipeng\"), plans to participate in subscribing to shares of Xihu Innovation (Hangzhou) Technology Innovation Achievement Transformation Venture Capital Partnership (Limited Partnership). Hangzhou Mipeng signed the Partnership Agreement on September 19, 2025. As a limited partner, Hangzhou Mipeng intends to subscribe to the corresponding capital contribution with 15 million yuan of its own funds. The partnership enterprise's investment objectives are to primarily conduct venture capital activities targeting companies in strategic emerging industries such as biomedicine and hard technology, focusing on investment opportunities in early-stage, small and medium-sized, and growth-stage enterprises.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0216","symbol_name":"研究试验","start_time":0,"source_url":"","article_id":"1127117941","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127117941","pubTimestamp":1758537998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that its controlled entity, Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) (\"Hangzhou Mipeng\"), plans to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161726":"生物医药","301096":"百诚医药","399441":"生物医药","BK0216":"研究试验"},"translate_title":"杭州生诚医药（301096.SZ）子公司杭州米鹏拟1500万元投资合伙企业，聚焦生物医药和硬科技战略性新兴产业","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"301096":1,"399441":1},"content_text":"Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. (301096.SZ) announced that its controlled entity, Hangzhou Mipeng Enterprise Management Partnership (Limited Partnership) (\"Hangzhou Mipeng\"), plans to participate in subscribing to shares of Xihu Innovation (Hangzhou) Technology Innovation Achievement Transformation Venture Capital Partnership (Limited Partnership). Hangzhou Mipeng signed the Partnership Agreement on September 19, 2025. As a limited partner, Hangzhou Mipeng intends to subscribe to the corresponding capital contribution with 15 million yuan of its own funds. The partnership enterprise's investment objectives are to primarily conduct venture capital activities targeting companies in strategic emerging industries such as biomedicine and hard technology, focusing on investment opportunities in early-stage, small and medium-sized, and growth-stage enterprises.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127117941","isCrawlerRequest":true}